Evidence map›Paper›PMID 39626795›Full record

ArticlePharmacology, biochemistry, and behavior2025

Region-specific neuroadaptations of CRF1 and CRF2 expression following heroin exposure in female rats.

Piper Schneider, Danielle Goldbaum, Ansh Agarwal, Ashton Taylor, Peyton Sundberg, Eliot L Gardner, Robert Ranaldi, Zhi-Bing You, Ewa Galaj

Abstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Piper SchneiderDepartment of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA.
Danielle GoldbaumDepartment of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA.
Ansh AgarwalNeuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Ashton TaylorNeuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Peyton SundbergDepartment of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA.
Eliot L GardnerNeuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Robert RanaldiThe Graduate Center of the City University of New York, New York, NY, USA; Department of Psychology, Queens College of the City University of New York, Flushing, NY, USA.
Zhi-Bing YouNeuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA.
Ewa GalajDepartment of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA. Electronic address: egalaj@colgate.edu.

Funding

Environmental Enrichment as a Treatment for Heroin Use DisorderSC3GM130430 · NIGMS · QUEENS COLLEGE · PI RANALDI, ROBERT · 2019 to 2022
$462k
The role of the nigrothalamic pathway in opioid-driven behaviorsR15DA057501 · NIDA · COLGATE UNIVERSITY · PI GALAJ, EWA JOANNA · 2023 to 2023
$405k
NIDA NIH HHS R15 DA057501NIGMS NIH HHS SC3 GM130430
6 · The paper itself

Abstract

While stress increases vulnerability to development of addiction, the recruitment of corticotropin releasing factor (CRF) with excessive drug use heightens the risk of stress-induced relapse. CRF signaling is transmitted via CRF1 and CRF2 receptors, but the roles of these receptors in heroin self-administration and related neuroadaptations of the CRF system within mesolimbic brain loci are not well understood. In this study, we first investigated the causal role of CRF1 and CRF2 receptors in heroin self-administration. Intracerebroventricular (ICV) microinjections of antalarmin (a CRF1 antagonist) or astressin-2B (a CRF2 antagonist) caused brief, dose-dependent reductions in heroin self-administration in female rats, suggesting that these receptors play a critical role in heroin-motivated behaviors. We then used western blotting to examine neuroadaptive changes to CRF1 and CRF2 receptor expression in key forebrain and midbrain regions associated with opioid addiction. Female Long Evans rats treated with escalating doses of heroin for 16 days demonstrated significantly higher naloxone-precipitated withdrawal symptoms than saline-treated rats. Heroin-treated rats showed a significant decrease in CRF1 receptor protein expression in the ventral tegmental area (VTA) and an increase in the nucleus accumbens (NAc) but no changes in the prefrontal cortex (PFC), insula, dorsal striatum (dSTR), dorsal hippocampus (dHippo), anterior hypothalamus (HYPTH), amygdala, or substantia nigra (SN) as compared to saline-treated rats. After chronic heroin exposure, CRF2 receptor expression was significantly downregulated in the dHippo, VTA and HYPTH but not in the other brain regions we investigated. The results of this study suggest that: (1) CRF1 and CRF2 receptors play an important role in self-administration and (2) heroin exposure may lead to region-specific neuroadaptation of CRF1 and CRF2 receptors. Such neuroadaptations might in part contribute to the continuation of drug use and stress-induced relapse.

Indexed as

HeroinReceptors, Corticotropin-Releasing HormoneAnimalsCorticotropin-Releasing HormoneCRF Receptor, Type 1FemalePeptide FragmentsPeptides, CyclicPyrimidinesPyrrolesRatsRats, Long-EvansSelf Administrationantalarminastressin-2BCorticotropin-Releasing HormoneCRF Receptor, Type 1CRF receptor type 2HeroinPeptide FragmentsPeptides, CyclicPyrimidinesPyrrolesReceptors, Corticotropin-Releasing HormoneCRF1CRF2Drug self-administrationHeroinNaloxoneNeuroadaptationsNucleus accumbensOpioidVentral tegmental areaWithdrawal symptoms

Identifiers

PMID39626795
PMCPMC11769769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.